Cambridge Innovation Capital

Cambridge Innovation Capital (CIC) is a venture capital firm based in Cambridge, UK, specializing in investing in deeptech and life sciences startups. Established to leverage the rich innovation ecosystem around the University of Cambridge, CIC manages over £500 million across its funds, focusing on supporting early to growth-stage companies. The firm plays a strategic role in fostering innovation by backing ventures that emerge from the Cambridge cluster, including university spinouts and collaborations with research institutes like the Wellcome Sanger Institute. CIC's investment portfolio reflects its emphasis on groundbreaking technology, with companies like CMR Surgical, known for its Versius robotic surgery system, and PragmatIC Semiconductor, which focuses on flexible electronics. The firm also invests in biotech firms like Microbiotica, which leverages the microbiome for therapeutic purposes, and quantum computing ventures such as Riverlane. With its commitment to sustainability and a robust focus on ESG (Environmental, Social, and Governance), CIC aims to create long-term value while fostering responsible business practices. The firm not only provides capital but also strategic support, often co-investing alongside other prominent funds and facilitating connections through initiatives like DeepTech Labs and Start Codon, two accelerators designed to help startups navigate early commercial challenges. Led by Managing Partner Andrew Williamson, CIC remains deeply integrated within the Cambridge ecosystem, collaborating with universities, research hubs, and industry leaders to drive the next wave of technological breakthroughs​.